Clinical Trials Browser

Completed × atezolizumab × Breast × Clear all

NCT02530489 2026-02-17

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Phase 2 Completed

37 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Completed

190 enrolled 12 charts

Breast Neoplasms

NCT04148911 2025-12-26

EL1SSAR

Phase 3 Completed

184 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT03371017 2025-11-12

IMpassion132

Phase 3 Completed

595 enrolled 37 charts

Triple Negative Breast Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

NCT03802604 2025-09-09

PROMETEO

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT03568656 2025-08-08

Study to Evaluate CCS1477 in Advanced Tumours

Phase 1/2 Completed

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03289962 2025-07-04

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Melanoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03206203 2024-12-12

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

Phase 2 Completed

106 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02708680 2024-12-04

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

Phase 1/2 Completed

89 enrolled 16 charts

Breast Neoplasms

NCT03726879 2024-11-05

IMpassion050

Phase 3 Completed

454 enrolled 28 charts

Breast Neoplasms

NCT03800836 2024-10-30

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 1 Completed

139 enrolled 24 charts

Breast Neoplasms

NCT03164993 2024-10-15

ALICE

Phase 2 Completed

Breast Neoplasms, Neoplasms, Triple Negative Breast Neoplasms

NCT03395899 2024-06-18

ECLIPSE

Phase 2 Completed

Breast Neoplasms

NCT04408118 2024-06-04

ATRACTIB

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03256344 2024-05-14

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Phase 1 Completed

36 enrolled 16 charts

BreastGastrointestinal

Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03650348 2024-04-22

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

Phase 1 Completed

BreastGastrointestinalGenitourinaryOther solid neoplasm

HER2-positive Breast Cancer

NCT04177108 2024-03-27

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 3 Completed

242 enrolled 12 charts

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases, Triple Negative Breast Neoplasms

NCT03125902 2024-03-26

IMpassion131

Phase 3 Completed

653 enrolled 33 charts

Triple Negative Breast Neoplasms

NCT02620280 2024-03-06

NeoTRIPaPDL1

Phase 3 Completed

Carcinoma, Ductal, Breast, Triple Negative Breast Neoplasms

NCT03853707 2024-02-20

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Phase 1/2 Completed

28 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT03197935 2023-10-26

IMpassion031

Phase 3 Completed

333 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT03464942 2023-07-19

AZTEC

Phase 2 Completed

Breast Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04584112 2023-03-15

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Phase 1 Completed

Triple Negative Breast Neoplasms

NCT05609903 2022-11-08

Anastase

Breast Neoplasms

NCT03232593 2022-08-24

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

BreastGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02425891 2022-07-19

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Phase 3 Completed

902 enrolled 27 charts 2 FDA

Triple Negative Breast Neoplasms

NCT02914470 2021-10-19

PROLOG

Phase 1 Completed

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02924883 2021-02-17

KATE2

Phase 2 Completed

202 enrolled 21 charts

Breast Neoplasms

NCT02605915 2020-02-05

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Phase 1 Completed

Breast Neoplasms